Clinical Trial Update: How Does the Diabetes Drug, Pioglitazone, Reduce Protein Loss in the Urine? [Phase 4]

View source ↗

Summary

A Phase 4 trial examining how pioglitazone might reduce protein loss in urine in people with type 2 diabetes; the current status of the study is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Nephropathy
• Type 2 Diabetes Mellitus

Drugs mentioned

• PIOGLITAZONE (Pioglitazone)

Snippet

Sponsor: Christchurch Hospital | Conditions: Diabetes Mellitus, Type 2 | Phase 4 | Status: UNKNOWN